Abstract Number: 676 • 2017 ACR/ARHP Annual Meeting
Immunosignature Autoantibody Profiles Provide Mechanistic Insight into Systemic Lupus Erythematosus and Differentiation from Symptomatically Overlapping Diseases
Background/Purpose: Diagnosis and monitoring of patients with SLE usually requires careful evaluation by a rheumatologist. However, difficulties in accurately quantifing disease and treatment response can…Abstract Number: 1293 • 2017 ACR/ARHP Annual Meeting
Indications for Cesarean Delivery in Systemic Lupus Erythematosus Pregnancies
Background/Purpose: Pregnant SLE women are at increased risk of cesarean delivery compared to pregnant women from the general population. Yet, to date, no one has…Abstract Number: 1786 • 2017 ACR/ARHP Annual Meeting
Lupus Nephritis Is Linked to Immunity to an Intestinal Commensal Lachnospiracaea Species
Background/Purpose: A transmissible agent has long been suspected in the pathogenesis of SLE, yet the potential contribution of members of the intestinal microbiome to the…Abstract Number: 2587 • 2017 ACR/ARHP Annual Meeting
KZR-616, a Selective Inhibitor of the Immunoproteasome, Shows a Promising Safety and Target Inhibition Profile in a Phase I, Double-Blind, Single (SAD) and Multiple Ascending Dose (MAD) Study in Healthy Volunteers
Background/Purpose: Proteasome inhibition is a standard of care for plasma cell malignancies. The first-generation inhibitor, bortezomib (BTZ), targets the constitutive proteasome and immunoproteasome and has…Abstract Number: 2974 • 2017 ACR/ARHP Annual Meeting
B Cell Binding Autoreactive VH4.34 Antibodies Are Specific to Lupus, Consist of Diverse Isotypes, and Are Associated with High Disease Activity and Lupus Nephritis
Background/Purpose: SLE is characterized by the dysregulation of humoral immunity including high levels of autoreactive IgG VH4.34 antibodies recognized by the rat anti-human idiotypic antibody…Abstract Number: 695 • 2017 ACR/ARHP Annual Meeting
Development of a Multimarker Model for the Detection of Systemic Lupus Erythematosus Based on New and Traditional Autoantibodies
Background/Purpose: Given the heterogeneity of clinical presentations, the diagnosis of Systemic Lupus Erythematosus (SLE) can be challenging, in particular in those patients presenting with early…Abstract Number: 1294 • 2017 ACR/ARHP Annual Meeting
Time to Pregnancy in Women with Systemic Lupus Erythematosus
Background/Purpose: Women diagnosed with systemic lupus erythematosus (SLE) during the reproductive period have fewer children than unaffected women. Multiple disease-related factors might influence family size…Abstract Number: 1801 • 2017 ACR/ARHP Annual Meeting
Quantifying Clinical and Economic Outcomes Associated with Chronic Corticosteroid Exposure in a US Population
Background/Purpose: Corticosteroids (CS) are commonly used for rheumatologic conditions, and known to cause systemic adverse events (AEs), particularly when used at high doses for prolonged…Abstract Number: 2600 • 2017 ACR/ARHP Annual Meeting
Plasma Cell and T-Cell Activity Downregulation during MMF Therapy in SLE May be Necessary for Successful Immunosuppression
Background/Purpose: MMF is a key therapy for moderate to severe SLE. MMF inhibits inosine monophosphate dehydrogenase, an enzyme needed in nucleotide synthesis required for lymphocyte…Abstract Number: 2979 • 2017 ACR/ARHP Annual Meeting
The Expression of Mitochondrial Molecules in Microparticle Immune Complexes in the Blood of Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by immune complexes, especially those with nuclear molecules bound by antinuclear antibodies. Although the…Abstract Number: 149 • 2017 Pediatric Rheumatology Symposium
Deficiency of Complement C4A or Low Copy Number of Total C4 Genes, HLA-DRB1*15 and HLA-DRB1*03 Are Strong Genetic Risk Factors for Pediatric SLE of European Descent
Background/Purpose: A complete genetic deficiency of complement C4 almost always leads to the pathogenesis of systemic lupus erythematosus (SLE) with childhood onset, although its prevalence…Abstract Number: 91 • 2017 Pediatric Rheumatology Symposium
Peri-pubertal Onset of Systemic Lupus Erythematosus is Associated with Shorter than Expected Adult Height
Background/Purpose: Patients with childhood-onset SLE (cSLE) have a higher incidence of renal disease and may receive more intensive immunosuppression as compared to individuals with adult-onset…Abstract Number: 13L • 2016 ACR/ARHP Annual Meeting
Low-Dose IL-2 Therapy in Refractory SLE: Results from Single Center Phase I/IIa Clinical Trial
Background/Purpose: Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…Abstract Number: 763 • 2016 ACR/ARHP Annual Meeting
Rituximab As a Corticosteroid-Sparing Agent in Patients with Systemic Lupus Erythematosus
Background/Purpose : The treatment of active systemic lupus erythematosus (SLE) remains problematic because the current treatment regimen based on corticosteroids and immunosuppressive agents have significant…Abstract Number: 1053 • 2016 ACR/ARHP Annual Meeting
Evaluating the Charla De Lupus (Lupus Chat)® Program’s Teen, Young Adult and Parent Support Group: Reaching the Hispanic/Latino Community through a Family Model of Support
Background/Purpose: Research shows that chronic illnesses such as SLE have multi-level impact on the family; it can be challenging for both patients & caregivers to…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 38
- Next Page »